Annual report pursuant to Section 13 and 15(d)

Accrued Liabilities and other Long-Term Liabilities (Tables)

v3.8.0.1
Accrued Liabilities and other Long-Term Liabilities (Tables)
12 Months Ended
Dec. 31, 2017
Components of Accrued Expenses and Other Long-Term Liabilities
Accrued expenses and other long-term liabilities, excluding National, consisted of the following ($ in thousands):
 
 
 
December 31,
 
 
 
2017
 
2016
 
Accrued expenses:
 
 
 
 
 
 
 
Professional fees
 
$
1,625
 
$
1,253
 
Salaries, bonuses and related benefits
 
 
5,279
 
 
2,846
 
Accrued expenses – related party
 
 
95
 
 
-
 
Accrued severance
 
 
-
 
 
53
 
Ovamed manufacturing rights - short term component
 
 
-
 
 
900
 
Research and development
 
 
4,046
 
 
394
 
Dr. Falk Pharma milestone (See Note 16)
 
 
3,059
 
 
2,634
 
Accrued royalties payable
 
 
1,411
 
 
263
 
Accrued coupon expense
 
 
1,087
 
 
463
 
Lease impairment
 
 
-
 
 
128
 
Other
 
 
1,030
 
 
1,148
 
Total accrued expenses
 
$
17,632
 
$
10,082
 
 
 
 
 
 
 
 
 
Other long-term liabilities:
 
 
 
 
 
 
 
Deferred rent and long-term lease abandonment charge
 
 
4,739
 
 
5,014
 
Total other long-term liabilities
 
$
4,739
 
$
5,014
 
National Holdings Corporation [Member]  
Components of Accrued Expenses and Other Long-Term Liabilities
National’s accounts payable and other accrued expenses as of September 30, 2017, consisted of the following ($ in thousands):
 
 
 
September 30,
 
 
 
2017
 
2016
 
Legal
 
$
877
 
$
1,346
 
Audit
 
 
176
 
 
198
 
Telecommunications
 
 
205
 
 
209
 
Data Services
 
 
464
 
 
425
 
Regulatory
 
 
540
 
 
444
 
Settlements
 
 
2,403
 
 
832
 
Deferred rent
 
 
497
 
 
65
 
Other
 
 
3,242
 
 
3,223
 
Total
 
$
8,404
 
$
6,742